Alpha Tau Medical Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DRTS Nasdaq 2836 www.alphatau.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpha Tau Medical Ltd.

DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing - Jun 3rd, 2026 8:52 am
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients - Jun 3rd, 2026 6:30 am
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - Jun 1st, 2026 7:00 am
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears - May 29th, 2026 7:03 am
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update - May 18th, 2026 2:01 pm
Alpha Tau to Participate in May Investor Conferences - May 18th, 2026 6:30 am
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study - May 11th, 2026 8:07 am
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET - May 11th, 2026 5:00 am
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma - May 8th, 2026 7:10 am
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma - May 8th, 2026 7:00 am
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute - May 7th, 2026 7:00 am
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab - May 5th, 2026 7:14 am
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 - May 4th, 2026 7:17 am
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies - Apr 27th, 2026 7:01 am
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel) - Apr 23rd, 2026 7:02 am
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial - Apr 23rd, 2026 7:01 am
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 - Mar 31st, 2026 7:15 am
Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased - Mar 19th, 2026 9:47 am
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference - Mar 16th, 2026 8:02 am
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update - Mar 9th, 2026 2:02 pm